A thermoplastic polyurethane resin composition comprising: a thermoplastic polyurethane resin; an ultraviolet absorber package comprising a benzotriazole compound (UVA1), and a triazine compound (UVA2) wherein the mass ratio of UVA1 to UVA2 is from 1:1 to 3:1; optionally, a hindered amine light stabilizer and/or an antioxidant compound; and wherein the thermoplastic polyurethane resin composition has a maximum ultraviolet transmittance of ≤3% in the wavelengths between 280 nm and 365 nm and an ultraviolet transmittance of ≤6% in the wavelengths between 365 nm and 370 nm when the thermoplastic polyurethane resin is formed into a film having a thickness of 6 mils and wherein the cumulative weight % of UVA1 and UVA2 in the polyurethane resin composition ranges from 0.5 wt % to 0.85 wt % based on the total weight of the polyurethane resin composition.

A thermoplastic polyurethane resin composition comprising: a thermoplastic polyurethane resin; an ultraviolet absorber package comprising a benzotriazole compound (UVA1), and a triazine compound (UVA2) wherein the mass ratio of UVA1 to UVA2 is from 1:1 to 3:1; optionally, a hindered amine light stabilizer and/or an antioxidant compound; and wherein the thermoplastic polyurethane resin composition has a maximum ultraviolet transmittance of ≤3% in the wavelengths between 280 nm and 365 nm and an ultraviolet transmittance of ≤6% in the wavelengths between 365 nm and 370 nm when the thermoplastic polyurethane resin is formed into a film having a thickness of 6 mils and wherein the cumulative weight % of UVA1 and UVA2 in the polyurethane resin composition ranges from 0.5 wt % to 0.85 wt % based on the total weight of the polyurethane resin composition.

Various embodiments disclosed relate to method for identification of preferred binding sites on intrinsically disorganized proteins (IDPs). The present disclosure includes methods including generating an IDP ensemble comprising one or more of the IDPs, sampling ligand interactions with the IDP ensemble to produce sampled ligand interactions, subjecting each of the sampled ligand interactions to an IDP ensemble docking, producing a differential binding score (DIBS) based on the sampled ligand interactions with the IDP ensemble docking, and modeling the DIBS to identify binding sites on the IDP ensemble.

Various embodiments disclosed relate to method for identification of preferred binding sites on intrinsically disorganized proteins (IDPs). The present disclosure includes methods including generating an IDP ensemble comprising one or more of the IDPs, sampling ligand interactions with the IDP ensemble to produce sampled ligand interactions, subjecting each of the sampled ligand interactions to an IDP ensemble docking, producing a differential binding score (DIBS) based on the sampled ligand interactions with the IDP ensemble docking, and modeling the DIBS to identify binding sites on the IDP ensemble.

Described herein is a method for determining a lymphocyte cell receptor chain sequence specific to a unique antigen, comprising: sorting a plurality of antigens into a plurality of reaction mixtures, wherein the sorting comprises adding a unique antigen of the plurality of antigens to a unique subset of the plurality of reaction mixtures such that two different unique antigens are not added to the unique subset; contacting each reaction with a biological sample comprising a plurality of lymphocytes; separating a target lymphocyte from a subset of the plurality of lymphocytes, wherein the target lymphocyte recognizes the unique antigen; after separating the target lymphocyte, sequencing nucleic acids of the target lymphocyte to obtain the lymphocyte receptor chain sequence, wherein the sequencing is performed by single-cell sequencing; and detecting the unique antigen, wherein the detecting comprises: computing a frequency of lymphocyte cells that express the lymphocyte receptor chain sequence.

Disclosed herein is a system for discovering a drug active site of protein using a pathogenic mutation. The system includes: a pathogenic mutation position detection unit for detecting a pathogenic mutation position corresponding to a pathogenic mutation in a three-dimensional structure of protein, using pathogenic mutation data containing information on a pathogenic mutation causing an abnormal protein function and protein structure data containing information on the three-dimensional structure corresponding to genetic sequencing of the protein; and a drug active site detection unit detecting a drug active site, corresponding to the pathogenic mutation position, and, to which a drug is bindable.

Disclosed herein is a system for discovering a drug active site of protein using a pathogenic mutation. The system includes: a pathogenic mutation position detection unit for detecting a pathogenic mutation position corresponding to a pathogenic mutation in a three-dimensional structure of protein, using pathogenic mutation data containing information on a pathogenic mutation causing an abnormal protein function and protein structure data containing information on the three-dimensional structure corresponding to genetic sequencing of the protein; and a drug active site detection unit detecting a drug active site, corresponding to the pathogenic mutation position, and, to which a drug is bindable.

A method can include receiving a protein sequence (S) of a hybrid repressor, determining an original compatibility score C(S), where the compatibility score C is a function of the protein sequence (S) and predicting, based on the compatibility score C, a performance of the hybrid repressor. The hybrid protein sequence includes a plurality of DNA-binding modules (DBMs) and a plurality of ligand-binding modules (LBMs).

A method can include receiving a protein sequence (S) of a hybrid repressor, determining an original compatibility score C(S), where the compatibility score C is a function of the protein sequence (S) and predicting, based on the compatibility score C, a performance of the hybrid repressor. The hybrid protein sequence includes a plurality of DNA-binding modules (DBMs) and a plurality of ligand-binding modules (LBMs).

The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.